Current and emerging therapies in unresectable and recurrent gastric cancer

Table 1 First line chemotherapy completed trials

Ref.	Arms	n	TTP/PFS (mo)	OS (mo)
Van Cutsem et al[7]	DCF vs CF	445	TTP: 5.6 vs 3.7	9.2 vs 8.6
			P < 0.001	P = 0.02
Al-Batran et al[8]	FLO vs FLP	220	PFS: 5.8 vs 3.9	10.7 vs 8.8
			P = 0.077
REAL-2[9]	ECF vs ECX vs EOF vs EOX	1002	PFS: 6.2 vs 6.7 vs 6.5 vs 7.0	9.9 vs 9.9 vs 9.3 vs 11.2
Kang et al[10]	XP vs FP	316	PFS: 5.6 vs 5.0	10.5 vs 9.3
SPIRITS[11]	CS vs S-1	298	PFS: 6.0 vs 4.0	13.0 vs 11.0
			P < 0.0001	P = 0.04
FLAGS[12]	CS vs CF	1053	PFS: 4.8 vs 5.5	8.6 vs 7.9
			P = 0.920	P = 0.20
Dank et al[13]	IF vs CF	333	TTP: 5.0 vs 4.2	9.0 vs 8.7
			P = 0.088
Guimbaud et al[14]	FOLFIRI vs ECX	416	PFS: 5.3 vs 5.8	9.5 vs 9.7
			P = 0.960	P = 0.95

DCF: Docetaxel/cisplatin/fluorouracil; CF: Cisplatin/fluorouracil; FLO: Fluorouracil/leucovorin/oxaliplatin; FLP: Fluorouracil/leucovorin/cisplatin; ECF: Epirubicin/cisplatin/fluorouracil; ECX: Epirubicin/cisplatin/capecitabine; EOF: Epirubicin/oxaliplatin/fluorouracil; EOX: Epirubicin/oxaliplatin/capecitabine; XP: Cisplatin/capecitabine; FP: Cisplatin/fluorouracil; CS: Cisplatin/S-1; SOX: S-1/oxaliplatin; IF: Irinotecan/fluorouracil; FOLFIRI: Fluorouracil/leucovorin/irinotecan.